JJJens Richardt Møllegaard Jepsen

Jens Richardt Møllegaard Jepsen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jens Richardt Møllegaard Jepsen has a total of 167 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Neurocognitive correlates of psychotherapeutic treatment response in pediatric obsessive-compulsive disorder: Results from the TECTO trial

    by Melanie Ritter, Christine Lykke Thoustrup, Nicole Nadine Lønfeldt, Sofie Heidenheim Christensen, Valdemar Uhre, Linea Pretzmann, Anna-Rosa Cecilie Mora-Jensen, Nicoline Løcke Jepsen Korsbjerg, Kerstin Jessica Plessen, Jens Richard Møllegaard Jepsen, et al.

  • Open Access

    Neurocognitive profiles in early childhood in relation to clinical and functional outcomes in middle childhood in offspring at familial high‐risk of schizophrenia or bipolar disorder: The Danish High‐Risk and Resilience Study

    by Nicoline Hemager, Jens Richardt Møllegaard Jepsen, Aja Neergaard Greve, Lotte Veddum, Anne Søndergaard, Mette Falkenberg Krantz, Ole Mors, Anne Amalie Elgaard Thorup, Merete Nordentoft, Maja Gregersen

    Background: Widespread neurocognitive impairments exist in children at familial high‐risk of schizophrenia (FHR‐SZ), whereas evidence is mixed in children at FHR of bipolar disorder (FHR‐BP). Neurocognitive heterogeneity is well‐established, but associations with longitudinal clinical and functional outcomes remain unexplored. Methods: In this prospective cohort study, 274 children (FHR‐SZ, n = 170, FHR‐BP, n = 104, 46.7% female, mean age 12.0 years, SD 0.25) provided neurocognitive data at baseline and clinical data at 4‐year follow‐up. The assessed neurocognitive functions included intelligence, processing speed, attention, memory, and executive functions. Axis I mental disorders, psychotic experiences, and functioning were ascertained through child and caregiver interviews. Dimensional psychopathology was reported by the caregiver. Three baseline neurocognitive subgroups (mildly impaired, typical, and above‐average) derived from hierarchical cluster analysis across FHR‐groups constituted categorical predictors with clinical and functional measures at follow‐up as outcomes. Results: Compared with children in the typical subgroup and after accounting for sex, outcome of interest and Any Axis I disorder at baseline, and FHR‐group, children in the mildly impaired subgroup at baseline had a threefold increased risk of any externalizing mental disorder (OR 2.9, 95% CI 1.3–6.5, p = .007) and a twofold increased risk of psychotic experiences (OR 2.0, 95% CI 1.0–3.8, p = .04) during middle childhood. Additionally, they had significantly higher dimensional symptom severity (Cohen's d range 0.27–0.43, p < .05) and poorer global functioning (Cohen's d = 0.48, p < .001) at follow‐up. Neurocognitive subgroup membership was non‐differentially associated with clinical and functional outcomes across FHR‐groups. Conclusions: A significantly impaired neurocognitive profile in early childhood confers risk for detrimental clinical and functional outcomes in middle childhood beyond that which can be attributed to pre‐existing clinical and functional states and constitutes a cross‐diagnostic, neurodevelopmental risk marker in these FHR‐groups. Early neurocognitive profiling is warranted, and future studies should investigate long‐term associations with mental disorders.


  • Open Access

    The Effect of Virtual Reality–Based Social Cognitive Training for Autistic Adults: Protocol for STEPS (Social Cognitive Training Enhancing Pro-Functional Skills) Randomized Clinical Trial

    by Johannes Andresen, Alberte C E Jeppesen, Anne Sofie Due, Lise Sandvig Mariegaard, Rizwan Parvaiz, Carsten Hjorthøj, Amy Elizabeth Pinkham, Merete Nordentoft, Gasper Letnar, Jens Richardt Møllegaard Jepsen, et al.

    Background: Autistic adults constitute a growing and largely overlooked population with limited clinical and research resources. Social cognitive impairments are key deficits faced by this population, significantly impacting social interactions, educational and vocational functioning, and quality of life. Interventions targeting social cognition in autistic adults have shown promising results. Recent studies investigating the effect of virtual reality (VR)–based interventions for autistic adults have provided preliminary evidence supporting the feasibility and effectiveness of using this innovative technology. These studies indicate that VR interventions can enhance functional and social skills and improve specific neurocognitive and social cognitive functions. However, large-scale randomized clinical trials are urgently needed to fully assess the effectiveness of VR-based interventions for autistic adults. Objective: This protocol aims to provide a comprehensive description of the design and methodology of the STEPS (Social Cognitive Training Enhancing Pro-Functional Skills) trial. Methods: STEPS is a clinical, randomized, assessor-blinded, parallel-group superiority trial. A total of 140 participants will be allocated to receive either virtual reality–based social cognitive training (VRSCT) + treatment as usual (TAU) or TAU alone. The experimental group will receive 12 weekly 1-hour sessions of VRSCT, aiming at improving psychosocial functioning and social cognition through exposure to virtual social environments. The intervention comprises 3 core modules, namely emotions, social understanding, and complex social interactions. The exact content and duration of TAU received by each participant will be mapped and documented upon trial completion. Assessments will be conducted at baseline, at cessation of the intervention (3 months post baseline), and at 6 months post baseline. Results: Participant enrollment began in May 2024. As of February 2025 (initial manuscript submission), 34 participants had been enrolled, increasing to 97 participants as of December 2025. Completion of enrollment is expected in April 2026. Data analysis is expected to begin in October 2026 following the final 6-month follow-up assessment. Results are anticipated in December 2026 and will be disseminated through peer-reviewed publications. Conclusions: To our knowledge, STEPS is the hitherto largest randomized clinical trial globally investigating the effect of VRSCT for autistic adults. The results of this innovative intervention approach may significantly advance research in the field of autism. VRSCT holds potential to improve psychosocial functioning, quality of life, and co-occurring clinical symptoms, and to reduce social cognitive deficits in autistic adults. Establishing evidence-based interventions is crucial for addressing the debilitating psychosocial challenges faced by this population, especially considering the absence of established gold-standard treatments.


  • Open Access

    Examining expressed maternal warmth and criticism in schizophrenia and bipolar disorder and their relations with child mental health compared to population-based controls

    by Anne Mai Pedersen, Tine Holm, Dorthe Kirkegaard Thomsen, Nicoline Hemager, Aja Neergaard Greve, Birgitte Klee Burton, Ditte Lou Gantriis, Ditte Ellersgaard, Katrine Søborg Spang, Camilla Austa Jerlang Christiani, et al.

    This study examined whether mothers with schizophrenia spectrum disorder (SZSD) or mothers with bipolar disorder express less warmth, and more criticism compared to controls and whether mothers’ expressed warmth and criticism are associated with child self-esteem and mental health outcomes. Sixty mothers with SZSD, 60 mothers with bipolar disorder, and 60 control mothers, and their 7-year-old children were included from The Danish High Risk and Resilience Study VIA 7. Expressed warmth and criticism were evaluated by coding Five Minute Speech Samples using the Family Affective Attitudes Rating Scale. Child self-esteem was assessed with the “I Think I Am.” Child global functioning was assessed with the Children’s Global Assessment Scale, mental health with the Child Behavior Checklist School-age version, and KIDSCREEN-10 captured quality of life. Results showed that mothers with SZSD and mothers with bipolar disorder did not differ from controls on expressed warmth or criticism. Across groups, expressed criticism showed robust associations with poorer child mental health outcomes also when controlling for child sex and maternal functioning. Diagnostic status did not affect maternal expressed warmth or criticism toward their child. However, because more expressed criticism can be associated with adverse child outcomes, interventions promoting more positive interpretations may aid child mental health.

  • Open Access

    The Effect of Virtual Reality-based Social Cognitive Training for Autistic Adults: A Study Protocol for STEPS (Social Cognitive Training Enhancing Pro-functional Skills), a Randomised Clinical Trial (Preprint)

    by Johannes Andresen, Alberte C. E. Jeppesen, Anne Sofie Due, Lise Sandvig Mariegaard, Rizwan Parvaiz, Carsten Hjorthøj, Amy Elizabeth Pinkham, Merete Nordentoft, Jens Richard Møllegaard Jepsen, Louise Birkedal Glenthøj

    BACKGROUND Autistic adults (AA) constitute a growing and largely overlooked population with limited clinical and research resources. Social cognitive impairments are key deficits faced by this population, significantly impacting social interactions, educational and vocational functioning, and quality of life. Interventions targeting social cognition in AA, have shown promising results. Recent studies investigating the effect of virtual reality (VR)-based interventions for AA have provided preliminary evidence supporting the feasibility and effectiveness of utilizing this innovative technology. These studies indicate that VR-interventions can enhance functional and social skills and improve specific neurocognitive and social cognitive functions. However, large scale, randomised, clinical trials are urgently needed to fully assess the effectiveness of VR-based interventions for AA. OBJECTIVE This protocol aims to provide a comprehensive description of the design and methodology of the STEPS trial. METHODS STEPS is a clinical, randomised, assessor-blinded, parallel-group superiority trial. A total of 140 participants will be allocated to receive either VR-based social cognitive training (VRSCT) + treatment as usual (TAU), or TAU alone. The experimental group will receive 12 weekly, one-hour sessions of VRSCT, aiming at improving psychosocial functioning and social cognition through exposure to virtual social environments. The intervention comprises three core modules: Emotions, Social Understanding, and Complex Social Interactions. The exact content and duration of TAU received by each participant will be mapped and documented upon trial completion. Assessments will be conducted at baseline, at cessation of the intervention (3 months post-baseline), and at 6 months post-baseline. RESULTS The trial is currently recruiting participants. The first participant was enrolled in May 2024. Completion of recruitment is expected in January 2026. Data analysis is expected to commence in summer 2026, following the final six-month follow-up assessment. Results are anticipated by fall 2026 and will be disseminated at international conferences and through peer-reviewed publications. CONCLUSIONS To our knowledge, STEPS is the hitherto largest randomised clinical trial globally investigating the effect of VRSCT for AA. The results of this innovative intervention approach may significantly advance research in the field of autism. VRSCT holds potential to improve psychosocial functioning, quality of life, co-occurring clinical symptoms and reduce social cognitive deficits in AA. Establishing evidence-based interventions is crucial for addressing the debilitating psychosocial challenges faced by this population, especially considering the absence of established gold-standard treatments. CLINICALTRIAL Registered at ClinicalTrials.gov (ID: NCT06438536). https://clinicaltrials.gov/study/NCT06438536?term=NCT06438536&rank=1

  • Clinical segmentation in 22q11.2 deletion syndrome: Cognitive impairments and additional genetic load

    by H. Schmock, Matt P. Stevenson, S. Hanebaum, A. Vangkilde, A. Rosengren, S.M. Weinsheimer, F. Skovby, C. Olesen, H. Ullum, W.F.C. Baaré, et al.


  • Cross-sectional associations between adaptive functioning and social cognitive and neurocognitive functions in adolescents with first-episode, early-onset schizophrenia spectrum disorders

    by J.R.M. Jepsen, J. Rydkjaer, B. Fagerlund, Cecilie K. Lemvigh, A.K. Pagsberg, B.Y. Glenthøj, B. Oranje

    Background: Few studies have explored associations between adaptive functioning and cognition in adolescents with early-onset schizophrenia spectrum disorders (EOS).Methods: Adaptive functioning, cognition, positive, negative, and general symptoms were characterized in adolescents with EOS and healthy controls. A modified scale of negative, respectively, general symptoms was used. Bivariate analyses identified correlates of adaptive functioning to be included in multivariate analysis.Results: Adolescents with EOS showed significant impairments of social- and neurocognitive functions (−0.86 < Cohen´s ds < −0.58) and adaptive functioning (Cohen´s d = −2.23). Visual memory, verbal working memory, processing speed, reaction time, social cognition, and modified negative and general symptoms correlated significantly with adaptive functioning. The multiple regression analysis revealed only verbal working memory as uniquely associated with adaptive functioning (explaining 22.7 % of its variance). Verbal working memory also associated significantly with adaptive functioning in the context of the nonsignificant modified negative and the significant modified general symptoms dimension.Conclusions: Adolescents with first-episode EOS had large impairments in adaptive functioning and moderate to large cognitive deficits. Verbal working memory was an important associate to concurrent adaptive functioning and may be a treatment target for trials to improve cognitive and adaptive functioning in adolescents with EOS.


  • Emotion regulation in 7‐year‐old children with familial high risk for schizophrenia or bipolar disorder compared to controls – The Danish High Risk and Resilience Study – VIA 7, a population‐based cohort study

    by Katrine Søborg Spang, Julie Hagstrøm, Ditte Ellersgaard, Camilla Christiani, Nicoline Hemager, Birgitte Klee Burton, Aja Neergaard Greve, Kirsten Rohr, Ditte Gantriis, Signe Vangkilde, et al.

    Objectives: Emotion regulation is a predictor of overall life outcome. Problems of emotion regulation are associated with multiple psychiatric disorders and could be a potential treatment target for improving well‐being and functioning. Children at familial high risk of severe mental illness have a markedly increased risk of various psychopathology and constitute a group at significant risk of emotion regulation problems. Investigations of emotion regulation in children at familial high risk of severe mental illness are sparse. Methods: We applied an instrument for assessing emotion regulation, the Tangram Emotion Coding Manual (TEC‐M), to a population‐based cohort of 522 7‐year‐old children born to parents diagnosed with either schizophrenia or bipolar disorder and matched controls. The TEC‐M is an ecologically valid, clinician‐rated observational test measure of spontaneous emotion regulation. We aimed to compare emotion regulation between risk groups and to investigate associations between emotion regulation and psychopathology and daily life functioning, and between emotion regulation and an acknowledged questionnaire‐based dysregulation profile. Results: In this early developmental phase, we found no between group differences in emotion regulation. We found a significant but weak negative association between emotion regulation and both child psychopathology and the presence of a dysregulation profile on the Child Behavior Checklist and a weak positive association between emotion regulation and current level of functioning. Conclusions: These findings contribute to the understanding of emotion regulation in familial high‐risk children and further studies of emotion regulation in children at familial high risk of severe mental illness are warranted.


  • Open Access

    Genetic assortative mating for schizophrenia and bipolar disorder

    by Oskar Hougaard Jefsen, Ron Nudel, Yunpeng Wang, Jonas Bybjerg-Grauholm, Nicoline Hemager, Camilla A. J. Christiani, Birgitte K. Burton, Katrine S. Spang, Ditte Ellersgaard, Ditte L. Gantriis, et al.

    Psychiatric disorders are highly polygenic and show patterns of partner resemblance. Partner resemblance has direct population-level genetic implications if it is caused by assortative mating, but not if it is caused by convergence or social homogamy. Using genetics may help distinguish these different mechanisms. Here, we investigated whether partner resemblance for schizophrenia and bipolar disorder is influenced by assortative mating using polygenic risk scores (PRSs). PRSs from The Danish High-Risk and Resilience Study—VIA 7 were compared between parents in three subsamples: population-based control parent pairs (N=198), parent pairs where at least one parent had schizophrenia (N=193), and parent pairs where at least one parent had bipolar disorder (N=115). The PRS for schizophrenia was predictive of schizophrenia in the full sample and showed a significant correlation between parent pairs (r=0.121, p=0.0440), indicative of assortative mating. The PRS for bipolar disorder was also correlated between parent pairs (r=0.162, p=0.0067), but it was not predictive of bipolar disorder in the full sample, limiting the interpretation. Our study provides genetic evidence for assortative mating for schizophrenia, with important implications for our understanding of the genetics of schizophrenia.


  • Early Antipsychotic Nonresponse as a Predictor of Nonresponse and Nonremission in Adolescents With Psychosis Treated With Aripiprazole or Quetiapine: Results From the TEA Trial

    by Anne Katrine Pagsberg, Amanda Krogmann, Pia Jeppesen, Laura von Hardenberg, Dea G. Klauber, Karsten Gjessing Jensen, Ditte Rudå, Marie Stentebjerg Decara, Jens Richardt Møllegaard Jepsen, Birgitte Fagerlund, et al.